The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?

Date publication

janvier 2026

Journal

CVIR endovascular

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LOFFROY Romaric

Tous les auteurs :
Müller-Hülsbeck S, Fanelli F, Haage P, Hamady M, Kobeiter H, Loffroy R, O'Sullivan G, Ratnam LA, van Rijswijk CSP, Ruffino MA, Wolf F, Morgan RA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41591606

Résumé

The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.

Référence

CVIR Endovasc. 2026 01 27;9(1):11